Invention Grant
- Patent Title: Disruption of EGFR-SAR1 interaction for cancer treatment
-
Application No.: US16254287Application Date: 2019-01-22
-
Publication No.: US10663465B2Publication Date: 2020-05-26
- Inventor: Yusong Guo , Pik Ki Lau , Yixin Lin
- Applicant: The Hong Kong University of Science and Technology
- Applicant Address: HK Clear Water Bay
- Assignee: The Hong Kong University of Science and Technology
- Current Assignee: The Hong Kong University of Science and Technology
- Current Assignee Address: HK Clear Water Bay
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/566 ; G01N33/573 ; C12N15/113 ; A61P35/00 ; A61K31/7088 ; A61K9/00 ; A61K31/713 ; G01N33/574 ; G01N33/50 ; G01N33/68
Abstract:
The present invention relates to the discovery that delivery of EGFR to cell surface requires EGFR-SAR1A binding. Thus, the invention provides a method for identifying inhibitors of EGFR-SAR1A binding, which can serve as therapeutic agents for treating conditions involving undesirable EGFR signaling. The invention also provides novel composition and its use that suppresses the specific binding between EGFR and SAR1A for the purpose of treating or preventing a condition involving undesired EGFR signaling.
Public/Granted literature
- US20190277844A1 DISRUPTION OF EGFR-SAR1 INTERACTION FOR CANCER TREATMENT Public/Granted day:2019-09-12
Information query
IPC分类:
